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Abstract
The creatine kinase-isoenzyme MB (CK-MB) mass assay is one of the laboratory tests used for the diagnosis of myocardial 
infarction. It is recommended, however, that reference limits should take gender and race into account. In the present study, we 
analyzed the plasma CK-MB mass and troponin levels of 244 healthy volunteers without a personal history of coronary artery 
disease and with no chronic diseases, muscular trauma or hypothyroidism, and not taking statins. The tests were performed 
with commercial kits, CK-MB mass turbo kit and Troponin I turbo kit, using the Immulite 1000 analyzer from Siemens Healthcare 
Diagnostic. The values were separated according to gender and showed significant differences by the Mann-Whitney test. Mean 
(± SD) CK-MB mass values were 2.55 ± 1.09 for women (N = 121; age = 41.20 ± 10.13 years) and 3.49 ± 1.41 ng/mL for men 
(N = 123; age = 38.16 ± 11.12 years). Gender-specific reference values at the 99th percentile level, according to the Medicalc 
statistical software, were 5.40 ng/mL for women and 7.13 ng/mL for men. The influence of race was not considered because of 
the high miscegenation of the Brazilian population. The CK-MB values obtained were higher than the 5.10 mg/mL proposed by 
the manufacturer of the laboratory kit. Therefore, decision limits should be related to population and gender in order to improve 
the specificity of this diagnostic tool, avoiding misclassification of patients.
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Cardiac troponins are considered to be the gold-stan-
dard biomarker for the detection of myocardial injury and, in 
their absence, the creatine kinase-isoenzyme MB (CK-MB) 
assay continues to be the other preferred laboratory test. A 
recent guideline for the redefinition of myocardial infarction 
has established the 99th percentile of the biomarkers for a 
reference population as the decision limit for the diagnosis 
of myocardial necrosis (1). Considering the analytical as-
pects of the biomarkers, the National Academy of Clinical 
Biochemistry (NACB) and the International Federation of 
Clinical Chemistry (IFCC) Committees recommend that 
each laboratory should establish the reference limit based 
on a healthy population and taking into account gender and 
race (2). Few studies establishing gender and ethnic differ-
ences for CK-MB mass reference limits are available in the 
literature (2-4). By analyzing seven CK-MB assays, Apple et 
al. (3) demonstrated 1.2 to 2.6 higher 99th percentile values 
for males vs females and substantial differences based on 
ethnicity (3). These higher values can be explained by the 
larger muscle mass found in men compared to women and 
by between-race differences. Because skeletal muscle is 
composed of a small amount of CK-MB (1-3%), it is expected 
that higher concentrations of this marker will be present in 
men and blacks (3). As a result of the great miscegenation 
of the Brazilian population, we are not able to separate 
groups based on race. On the other hand, gender-specific 
reference limits should be established and adopted for 
clinical decisions.
Material and Methods
Our study cohort comprised 244 healthy volunteers 
without a personal history of coronary artery disease and 
with no chronic diseases, muscular trauma or hypothyroid-
ism, and not taking statins (5). They were selected from 
the employees of the Heart Institute of the Medical School, 
University of São Paulo. The sample size was based on the 
guidelines elaborated by the Clinical and Laboratory Stan-
dards Institute (CLSI), which recommends a minimum of 120 
samples per group of healthy individuals for an adequate 
Gender differences and CK-MB levels 237
www.bjournal.com.br Braz J Med Biol Res 44(3) 2011
statistical establishment of reference limits (6).
The study subjects were divided into two groups ac-
cording to gender: females (N = 121; age = 41.20 ± 10.13 
years) and males (N = 123; age = 38.16 ± 11.12 years). The 
study participants were instructed not to perform physical 
exercise for 48 h before blood collection. Blood was col-
lected by venipuncture and placed in gel separator tubes. 
After clot formation the tubes were centrifuged and the 
tests were run immediately after serum separation. The 
cardiac markers were measured in a chemiluminescent im-
munometric assay (turbo CK-MB mass and turbo Troponin 
I) using the Immulite 1000 analyzer (Siemens Healthcare 
Diagnostics Inc., UK). The procedure consists of the binding 
of the molecule being measured (CK-MB or Troponin I) to 
an antibody-coated bead, where it is captured and held. 
Then, a second antibody, a murine monoclonal antibody 
labeled with alkaline phosphatase, binds to the captured 
substance being held on the bead. A chemiluminescent 
substrate is added to the test unit and the 
alkaline phosphatase label catalyzes the 
substrate and photons of light are released. 
The photon light output is measured by 
a Photomultiplier tube and converted to 
count per second (CPS).
Troponin I was run together with 
CK-MB mass to increase the chance of 
detecting any myocardial damage in the 
study group. The within-laboratory preci-
sion, within-run and between-run precision, 
expressed as coefficient of variation (CV), 
were determined using commercial control 
samples (level 1 from Siemens Healthcare 
Diagnostics Inc.) processed in duplicate 
over 30 days for a total of 60 replicates. 
The D’Agostino-Pearson test was used to 
establish normal or nonparametric value 
distribution. The nonparametric percentile method was per-
formed according to the standard protocol of CLSI C-28-A3 
(6). Suspected outliers were eliminated using the Tukey 
method, which defines outliers as three interquartile ranges 
below the 25th percentile or above the 75th percentile. The 
Mann-Whitney test was performed to determine whether 
gender-related values were different. The 99th percentile 
reference interval was determined using the Medicalc 
statistical software, version 9.6.4.0, Belgium. P ≤ 0.05 was 
considered to be statistically significant.
Results
Total and gender-specific values for CK-MB mass (ng/
mL) are reported in Table 1. The results for both genders as 
a whole (total) and for the female group followed a nonpara-
metric distribution, whereas the values for the male group 
followed a normal distribution. The 99th percentile for total 
CK-MB was 6.63 ng/mL, higher than the value suggested 
by the manufacturer of our assay (5.10 ng/mL). Concern-
ing the gender-related median, a significant difference was 
found in the values for the male group, which were higher 
than the values for the female group (3.49 vs 2.55 ng/mL; 
P < 0.0001; Figure 1). Likewise, the 99th percentile was 
1.3-fold higher in men compared to women (7.13 vs 5.40 
ng/mL; Table 1).
Recent guidelines recommend that the cardiac marker 
assays should have a total imprecision of 10% at the 
medical decision limit (99th percentile) (1,2). For CK-MB 
mass, the assay had a CV of 5.6% at a concentration of 
6.48 ng/mL, a value close to the medical decision limits 
established in our study. For troponin I, the CV obtained 
was 8.59% at a concentration of 0.84 ng/mL. Based on 
our results, we adopted a reference limit for troponin I of 
0.6 ng/mL, as suggested by another study in the literature 
(3), as the concentration that will reach the analytical goal 
proposed by others (1,2). Almost all the troponin I obtained 
Figure 1. Comparison of female and male CK-MB concentra-
tions. Box-and-whisker representation of the results. CK-MB 
mass = creatine kinase-isoenzyme MB mass. CK-MB values for 
males (N = 123) were significantly different from those for fe-
males (N = 121; P < 0.0001, Mann-Whitney test).
Table 1. CK-MB mass concentrations by gender.
Total Males Females
Sample size 244 123 121
Concentration range (ng/mL) 0.72-6.64 0.73-7.19 0.72-5.40
Mean and standard deviation (ng/mL) 3.03 ± 1.34 3.49 ± 1.41 2.55 ± 1.09
95%CI of the mean (ng/mL) 2.86-3.20 3.24-3.75 2.35-2.74
Median (ng/mL) 2.95  3.34* 2.33
95%CI of the median (ng/mL) 2.64-3.15 3.12-3.63 2.09-2.62
99th percentile (ng/mL) 6.63 7.13 5.40
90%CI of the 99th percentile (ng/mL) NA 6.77-7.50 NA
CK-MB mass = creatine kinase-isoenzyme MB mass; NA = not applicable. *P < 
0.0001 for males vs females (Mann-Whitney test).
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from volunteers resulted in values <0.2 ng/mL, indicating 
the absence of myocardial necrosis.
Discussion
For the diagnosis of myocardial necrosis, the NACB 
recommends the use of CK-MB measurements in two 
consecutive samples exceeding the 99th percentile of 
values for a gender-specific reference control group (7). 
Unfortunately, few manufacturers report medical decision 
limits for the CK-MB mass at the 99th percentile level and 
based on gender specificity. Reference limits for CK-MB 
mass in women and men were different in our population 
and similar literature results (Table 1) (3,4). This is probably 
the consequence of a greater body muscle mass in men and 
indicates the importance of different decision-limit values 
based on gender in clinical practice. The 99th percentile 
claimed by the in vitro diagnostic company in their pack-
age insert used in our laboratory is 5.10 ng/mL, without 
any information about a gender-specific reference range. 
In the present study, two decision limits were established 
for the values at the 99th percentile level: 5.40 ng/mL for 
women and 7.13 ng/mL for men. The gender-related values 
and the total population cut-off were higher than those sug-
gested by the manufacturer. The disagreement in results 
could be explained by differences in race composition 
between the populations. Four CK-MB assays tested by 
Apple et al. (3) showed higher (1.2- to 2.7-fold; P < 0.02) 
mean concentrations for blacks compared to Caucasians. 
Henny and Hyltoft (8) suggested that decision limits should 
be adapted to the population because of the differences 
detected in analyses in some of them. Thus, regional and 
racial differences may influence the level of many bio-
markers. The authors mentioned the impact of ethnicity 
in developing countries and the difficulty to compare the 
data produced by these countries to the results reported 
in developed ones. Unfortunately, the manufacture makes 
no mention of the race of its reference group. Because of 
the high miscegenation of our population, a race influence 
on CK-MB levels is unlikely. 
These new reference ranges of CK-MB values were 
applied retrospectively to 216 consecutive samples of pa-
tients with symptoms of acute coronary syndromes (ACS), 
who were included in a research protocol performed in our 
hospital (data not shown). A total of 112 study samples 
were from the male group: 26 from patients with ACS and 
86 from patients with other cardiac causes. In the latter 
group, 25.6% would have been misclassified if had used 
the manufacturer reference range instead of our own. No 
misclassification was found in the ACS group. Concerning 
the female group (N =104), because the cut-off was close 
to that of the manufacturer, only 5 (5.6%) patients would 
have been misclassified.
One question raised is why not definitely replace the 
CK-MB test with the troponin test, which is considered to 
be the gold standard of cardiac markers for myocardial 
infarction (1). A College of American Pathologists survey 
study of the turnaround time of cardiac markers performed 
at 159 hospitals, mainly in North America, in 2004, showed 
that CK-MB was still used by 92.7% of the participating 
laboratories (9). In a survey conducted during the 2008 
audio conference of the American Association for Clinical 
Chemistry, only 22.2% of the participating laboratories used 
only troponin as a cardiac biomarker, whereas about 63.3% 
performed both troponin and CK-MB mass tests (10). 
We must also consider that, in Brazil, Public Health Insur-
ance does not cover the troponin test, but only the CK-MB 
test. Finally, with the advent of high-sensitivity tests, very 
low amounts of circulating troponin are detectable even in 
a reference population. In a study conducted by Omland et 
al. (11), troponin levels were associated with the incidence 
of cardiovascular death and heart failure in a population 
with stable coronary artery disease, but not independently 
associated with the incidence of myocardial infarction. Thus, 
the authors pointed out that, as the troponin tests become 
more sensitive, the low-level elevations of troponin will be 
less specific for acute myocardial injury. Taking into account 
these considerations, we believe that the association of 
the troponin assay with another biochemical marker like 
CK-MB mass will increase the specificity of the 2 markers 
for the detection of myocardial injury. 
Therefore, we suggest the cut-off values for CK-MB of 
7.1 ng/mL for men and 5.4 ng/mL for women in our popula-
tion. The adoption of decision limits for CK-MB based on 
gender will improve the specificity of this diagnostic tool, 
avoiding misclassification of patients, which overwhelms 
emergency rooms, with social implications for health insur-
ance and employment. 
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